Costimulatory molecule immune enhancement in a plasmid vaccine model is regulated in part through the Ig constant-like domain of CD80/86

被引:14
作者
Agadjanyan, MG
Chattergoon, MA
Flolterman, MJ
Monzavi-Karbassi, B
Kim, JJ
Dentchev, T
Wilson, D
Ayyavoo, V
Montaner, LJ
Kieber-Emmons, T
Sekaly, RP
Weiner, DB
机构
[1] Univ Penn, Sch Med, Dept Pathol & Lab Med, Stellar Chance Labs 505, Philadelphia, PA 19104 USA
[2] Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA
[3] Inst Mol Med, Huntington Beach, CA 92649 USA
[4] Univ Illinois, Dept Surg, Chicago, IL 60612 USA
[5] Univ Montreal, Ctr Rech, Montreal, PQ, Canada
[6] Univ Montreal, Ctr Hosp, Montreal, PQ, Canada
关键词
D O I
10.4049/jimmunol.171.8.4311
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
There is great interest in understanding the role of costimulatory molecules in immune activation. In both the influenza and HIV DNA immunization models, several groups have reported that coimmunization of mice with plasmids encoding immunogen and CD86, but not CD80, effectively boosts Ag-specific T cell activation. This difference in immune priming provided an opportunity to examine the functional importance of different regions of the B.7 molecules in immune activation. To examine this issue, we developed a series of chimeric CD80 and CD86 constructs as well as deletion mutants, and examined their immune activating potential in the DNA vaccine model. We demonstrate that the lack of an Ig constant-like region in the CD80 molecule is critically important to the enhanced immune activation observed. CD80 C-domain deletion mutants induce a highly inflammatory Ag-specific cellular response when administered as part of a plasmid vaccine. The data suggest that the constant-like domains, likely through intermolecular interactions, are critically important for immune regulation during costimulation and that engineered CD80/86 molecules represent more potent costimulatory molecules and may improve vaccine adjuvant efficacy.
引用
收藏
页码:4311 / 4319
页数:9
相关论文
共 53 条
[41]  
2-K
[42]   Functional equivalency of B7-1 and B7-2 for costimulating plasmid DNA vaccine-elicited CTL responses [J].
Santra, S ;
Barouch, DH ;
Jackson, SS ;
Kuroda, MJ ;
Schmitz, JE ;
Lifton, MA ;
Sharpe, AH ;
Letvin, NL .
JOURNAL OF IMMUNOLOGY, 2000, 165 (12) :6791-6795
[43]   Structural basis for co-stimulation by the human CTLA-4/B7-2 complex [J].
Schwartz, JCD ;
Zhang, XW ;
Fedorov, AA ;
Nathenson, SG ;
Almo, SC .
NATURE, 2001, 410 (6828) :604-608
[45]  
Sperling AI, 1996, J IMMUNOL, V157, P3909
[46]   Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses [J].
Stamper, CC ;
Zhang, Y ;
Tobin, JF ;
Erbe, DV ;
Ikemizu, S ;
Davis, SJ ;
Stahl, ML ;
Seehra, J ;
Somers, WS ;
Mosyak, L .
NATURE, 2001, 410 (6828) :608-611
[47]   SR-ALPHA PROMOTER - AN EFFICIENT AND VERSATILE MAMMALIAN CDNA EXPRESSION SYSTEM COMPOSED OF THE SIMIAN VIRUS-40 EARLY PROMOTER AND THE R-U5 SEGMENT OF HUMAN T-CELL LEUKEMIA-VIRUS TYPE-1 LONG TERMINAL REPEAT [J].
TAKEBE, Y ;
SEIKI, M ;
FUJISAWA, JI ;
HOY, P ;
YOKOTA, K ;
ARAI, KI ;
YOSHIDA, M ;
ARAI, N .
MOLECULAR AND CELLULAR BIOLOGY, 1988, 8 (01) :466-472
[48]   CLUSTAL-W - IMPROVING THE SENSITIVITY OF PROGRESSIVE MULTIPLE SEQUENCE ALIGNMENT THROUGH SEQUENCE WEIGHTING, POSITION-SPECIFIC GAP PENALTIES AND WEIGHT MATRIX CHOICE [J].
THOMPSON, JD ;
HIGGINS, DG ;
GIBSON, TJ .
NUCLEIC ACIDS RESEARCH, 1994, 22 (22) :4673-4680
[49]   Immunomodulatory effects of a plasmid expressing B7-2 on human immunodeficiency virus-1-specific cell-mediated immunity induced by a plasmid encoding the viral antigen [J].
Tsuji, T ;
Hamajima, K ;
Ishii, N ;
Aoki, I ;
Fukushima, J ;
Xin, KQ ;
Kawamoto, S ;
Sasaki, S ;
Matsunaga, K ;
Ishigatsubo, Y ;
Tani, K ;
Okubo, T ;
Okuda, K .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1997, 27 (03) :782-787
[50]   CTLA-4 ligation blocks CD28-dependent T cell activation [J].
Walunas, TL ;
Bakker, CY ;
Bluestone, JA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 183 (06) :2541-2550